Tyrogenex Presents Final Results from Phase 1 Study of X-82 for Wet AMD at the 15th EURETINA Congress
NEEDHAM, Mass., & PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Tyrogenex, focused on next-gen targeted therapeutics for ophthalmology, presented data from its phase 1 safety study of orally-administered X-82 in patients for wet AMD at EURETINA Congress.
